Announcement on Receiving the "Drug Clinical Trial Approval Notification" for Class 1 Innovative Drug NH302 Injection

Jiangsu Nhwa Pharmaceutical Co., Ltd.·August 18, 2026·2 pages

✨ AI Summary

Jiangsu Enhua Pharmaceutical received approval from the NMPA for its Class 1 chemical drug NH302 injection to commence clinical trials for acute pain. Pre-clinical studies show strong analgesic effects. The company expects this to enrich its pain management product line, though clinical trials are long and costly.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002262

Securities Abbreviation: Enhua Pharmaceutical

Announcement Number: 2026-032

Jiangsu Enhua Pharmaceutical Co., Ltd.

Announcement on Receiving the "Drug Clinical Trial Approval Notification" for Class 1 Innovative Drug NH302 Injection

The Company and all members of the Board of Directors guarantee the authenticity, accuracy, and completeness of the announcement and assume joint and several liability for any false representations, misleading statements, or material omissions therein.

Jiangsu Enhua Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the "Drug Clinical Trial Approval Notification" for Class 1 chemical drug NH302 injection, issued by the National Medical Products Administration (hereinafter referred to as the "NMPA"), and will commence clinical trials in the near future. The relevant situation is hereby announced as follows:

I. Basic Information of the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.